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iven the widespread use of potent acid suppressive
therapies and primary caregivers’ increasing com-
ort with prescribing these medications at high doses, the
atient population presenting to gastroenterologists for
ymptoms of gastroesophageal reflux disease (GERD) has
hanged. Whereas previous consultation often revolved
round the control of erosive disease and other mucosal
anifestations of GERD, and terminated with the prescrip-
ion of proton pump inhibitor (PPI) therapy, gastroenter-
logists often now only enter the scene after failure of PPI
herapy, for symptoms either resistant or only partially
esponsive to these medications. Because of the high pro-
ortion of subjects with esophagitis who are healed with
PI,1,2 upper endoscopy of such individuals is low yield,3
ith only a small minority demonstrating erosive disease.
The care of such patients is challenging. High-quality
vidence supporting useful diagnostic testing or alterna-
ive effective therapies is largely lacking. However, the
umber of subjects with GERD symptoms incompletely
r nonresponsive to PPI therapies is high, and their
tilization of healthcare resources is substantial. The
urpose of this mini-review is to examine the definition
nd epidemiology of esophageal GERD symptoms in-
ompletely responsive to PPI therapy, the potential
athophysiologic mechanisms behind these symptoms,
he differential diagnosis and evaluation of such patients,
nd current and developing therapeutic options.
Definition and Epidemiology
Incomplete response of classic GERD symptoms,
uch as heartburn and regurgitation, to PPI therapy is
ommon. A recent American Gastroenterological Associ-
tion survey of 1000 subjects receiving PPI therapy for
ERD symptoms demonstrated that 38% reported resid-
al symptoms, and that more than half of those with
esidual symptoms took additional medication to con-
rol symptoms, most commonly over-the-counter antac-
ds (47%).4 A systematic review of symptom control in
rials of PPI therapy for GERD demonstrated that only a
inority of subjects with GERD achieved complete
ymptom control on therapy.5 Interestingly, this analysis
emonstrated that subjects entering GERD trials as non-
rosive patients were less likely to achieve symptom con-
rol than were erosive patients (37% vs 57%; P  .001).Despite the common nature of incomplete control of
ERD symptoms on PPI therapy, a universal definition
or “PPI-refractory GERD” is lacking. Is a subject PPI
efractory after incomplete control at once daily dosing?
hould twice daily (BID) or other regimens be required
efore a subject is considered refractory? Previous work
emonstrates that a substantial number of subjects (as
igh as 32%) on daily PPI continue to demonstrate ab-
ormal distal esophageal acid exposures, and that this
roportion can be lowered to single digits by increasing
tandard therapy to BID PPI.6,7 However, US Food and
rug Administration-approved dosing of these medica-
ions does not extend to BID therapy. Because BID ther-
py is commonly employed and has been recommended
s a therapeutic trial in subjects refractory to once daily
herapy,8 for purposes of this discussion, refractory sub-
ects will be considered as having troublesome symptoms
espite BID PPI therapy.
The Montreal classification defines GERD as “a condi-
ion which develops when the reflux of stomach contents
auses troublesome symptoms and/or complications.”9
hich symptoms are considered “troublesome” is left to
he discretion of the patient. This classification further
ivides GERD into esophageal and extraesophageal syn-
romes, and subdivides esophageal syndromes as those
anifest with esophageal injury, such as esophagitis, stric-
ure, or Barrett’s esophagus, and those manifest solely by
roublesome symptoms. In such a scheme, a subject with
eartburn and an incomplete response to PPI, who had no
istory of mucosal disease on or off therapy, in whom
ERD was causing bothersome symptoms, would be clas-
ified as a nonerosive typical esophageal reflux patient.
Differential Diagnosis of Residual
Reflux Symptoms on PPI
When patients have symptoms of ongoing reflux
espite maximal PPI therapy, the main clinical question
s: Are these symptoms related to gastroesophageal re-
ux? There is a broad differential diagnosis to consider,
nd potential etiologies may be gastrointestinal (GI) or
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8
on-GI related. The GI etiologies can be esophageal or
onesophageal, and the former may be reflux or non-
eflux related. There are 3 major categories of reflux-
elated causes. First is reflux with ongoing acid exposure.
tiologies include incorrect medication dose timing,
edication noncompliance, residual pathologic acid se-
retion, rapid PPI metabolism, a hypersecretory state, a
ignificant anatomic abnormality like a large hiatal her-
ia, excess reflux during transient lower esophageal
phincter relaxations (tLESRs), or defective esophageal
ucosal barrier function. Second is reflux of nonacid
aterial from either the stomach or the duodenum (e.g.,
ile). Third is reflux of normal amounts of weakly acidic
r alkaline contents into a hypersensitive esophagus.
The non-reflux–related esophageal causes include dys-
otility syndromes such as achalasia, esophageal spasm,
r scleroderma; eosinophilic esophagitis; pill esophagitis;
nd infectious esophagitis. In the absence of structural,
otility, or inflammatory causes, functional heartburn or
unction chest pain should be considered, depending on
he primary symptom.
It is beyond the scope of this mini-review to discuss the
onesophageal causes of reflux-type symptoms in detail,
ut typical conditions to consider include gallbladder
isease, malignancy in the GI system or surrounding
rgans, cardiovascular disease, and musculoskeletal dis-
ase.
Mechanisms of Persistent Reflux
Symptoms
The putative mechanisms of PPI-refractory GERD
ymptoms are illustrated in Figure 1. Similar to the
ifferential diagnosis for symptoms, the mechanisms can
e either reflux or non-reflux related.
Elevated Acid Exposures Despite Therapy
As noted, relatively few patients maintain pathologic
evels of esophageal acid exposure despite appropriately
dministered BID therapy.6,7 There are several mechanisms
o explain elevated esophageal acid exposures despite PPI
herapy. First, there may be medication noncompliance.
nly 60%–67% of PPI prescriptions are actually filled, and
ompliance with medication is 50% at 1 year after pre-
cription.10 A related issue is whether the medication is
aken correctly. The PPI must be activated within the pari-
tal cell canaliculus for binding with the H-K ATPase.11
ecause the greatest number of pumps are present in the
reprandial state, the typical recommendation is to admin-
ster the medication before breakfast.11,12 Despite instruc-
ion, more than half of patients dose PPIs suboptimally.13
Another explanation may be related to PPI metabo-
ism. Although individual PPIs are metabolized by differ-
nt hepatic cytochrome isoenzymes, there is patient-level
ariability in drug metabolism. It is conceivable that a orapid” PPI metabolizer might not achieve high enough
erum levels for adequate acid suppression,14 –16 but this
s likely a small proportion of treatment failures. Noc-
urnal acid breakthrough is also related to PPI metabo-
ism, and may be responsible for persistent symptoms in
ome patients,17 but the correlation between symptoms
nd acid exposures is poor.18
In the correct clinical context, for example if small
owel ulceration accompanies refractory reflux and diar-
hea, a hypersecretory state such as Zollinger-Ellison syn-
rome could be considered. However, this remains an
ncommon cause of refractory reflux, and PPIs are the
ecommended initial treatment for Zollinger-Ellison syn-
rome.19
A final mechanism involves disruption of the antire-
ux barrier at the gastroesophageal junction, due to
ither a hiatal hernia or a hypotensive lower esophageal
phincter (LES). A number of medications and foods (eg,
nticholinergics, estrogens, calcium-channel blockers, ni-
roglycerine, benzodiazepines, chocolate, caffeine, alco-
ol, peppermint) cause decreased LES pressures.20,21
Transient Lower Esophageal Sphincter
Relaxations
tLESRs are the major mechanism of both physi-
logic and pathologic reflux.22–24 They differ from swal-
ow-induced LES relaxations in that they are not associ-
ted with an esophageal peristaltic wave and the duration
f LES relaxation is longer.25 Gastric distention, medi-
ted by a vagal reflex arc, can prompt tLESRs, allowing
or venting gas and, in patients with reflux disease, the
eflux of gastric contents.24,26
PPIs do not have any effect on tLESRs; they are acid-
uppressive medications, but do not inhibit the reflux of
astric contents. In patients where tLESRs are the pre-
ominant pathophysiologic mechanism of reflux, PPIs
ay neutralize gastric acid, but do not affect the under-
ying cause. The observation that tLESRs can be inhibited
y gamma aminobutyric acid receptor type B (GABA)
gonists, however, has opened new therapeutic possibil-
ties (see below).27,28
Reflux of Nonacidic Gastroduodenal Contents
PPIs convert acidic refluxate to nonacidic reflux-
te.29 However, reflux of nonacidic fluid can also be
ssociated with symptoms of reflux. Combined mul-
ichannel intraluminal impedance and pH monitoring
llows detection of nonacid reflux.30 –32 This technology is
ble to characterize patients with ongoing reflux symp-
oms, but negative traditional pH testing because imped-
nce monitoring can identify reflux of gas, mixed reflux-
te, and weakly or nonacid reflux.33–35 Such reflux events
ay be promoted by tLESRs, hypotensive LES, a gastro-
sophageal junction anatomic defect, or a combination











Mini-Reviews and Perspectives continuedeflux of mixed gaseous/liquid content are primary de-
erminants of symptom generation.37
Bile acid reflux is also a potential cause of residual
ymptoms. Bile reflux can potentiate erosive esophagitis
aused by an acidic refluxate, as well cause PPI-refractory
igure 1. Putative etiologies of PPI-refractory GERD symptoms and po
or PPI-refractory GERD symptoms (blue shading) with corresponding t
inked to the anatomic area of interest (solid black line).eflux symptoms in the absence of acid exposure.38,39 dSimulation of Mechanoreceptors Owing to
Distention With Refluxate and Gas
Esophageal mechanoreceptors mediate stretch stim-
li, and may be responsible for reflux symptoms.40 In
ealthy volunteers, heartburn and chest pain can be in-
l therapies. Each of the eleven boxes describes a potential mechanism
ies targeting this mechanism (orange shading). The mechanism is alsotentia
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1
oon distension41 in a process that can be independent of
he presence of acid,42,43 or exacerbated by it.44 Some
atients with functional heartburn may have sensitiza-
ion of these receptors as a mechanism of their symp-
oms.40,42 In addition, stimulation of mechanoreceptors
ay trigger a vagally mediated reflux arc that induces
ough, bronchospasm, or other extraesophageal symp-
oms.36,45– 47
Defective Mucosal Barrier Function
The nonkeratinized, stratified squamous esopha-
eal epithelium provides a robust physical barrier against
aterial of wide-ranging temperature, pH, and osmolal-
ty. The ultrastructure of the esophageal mucosa has
een well described, and although complexes of tight
unctions are responsible for the majority of barrier func-
ion,48,49 basolateral chloride/bicarbonate exchangers also
apidly normalize intracellular pH.50 In addition to pro-
onged acid exposure, factors such as increasing hyperos-
olality of oral intake, smoking, and ethanol may lead to
ucosal barrier dysfunction.51–53
Hypersensitivity to Normal Exposures
A subset of patients with symptoms of reflux and
ormal upper endoscopies have normal esophageal acid
xposures but a strong correlation between physiologic
eflux events and symptoms.33,34,40 Visceral hypersensitiv-
ty is likely the underlying mechanism,54 although the
xact pathophysiology is unknown. One candidate for
ocal modulation of symptoms is an acid-sensing re-
eptor in the transient receptor potential cation chan-
el class.40 In preliminary studies, the capsaicin or
anilloid receptor 1 is localized in sensory neurons,
auses burning pain in response to an acid stimulus,
nd has been shown to have increased expression in
sophagitis patients.55,56
Poor Peristalsis and Delayed Gastric
Emptying
If esophageal luminal clearance of noxious stimuli
s impaired, then ongoing symptoms may result. In ad-
ition to gravity, the major mechanism of esophageal
uminal clearance is peristalsis.49 Underlying etiologies to
onsider include aperistalsis, ineffective esophageal mo-
ility, and esophageal spasm.20,57 Similarly, if there is
astric dysmotility from gastroparesis of any etiology and
he stomach does not empty in a timely fashion, not only
an ongoing gastric distention trigger tLESRs, but the
ncreased volume of gastric contents themselves may
romote reflux.24
Functional Heartburn/Chest Pain Syndrome
In the absence of other mechanisms, it is common
or reflux symptoms to be functional in nature. Indeed,
n recent studies more than half of the PPI-refractory w
0
eflux symptom population did not have evidence of any
astroesophageal reflux on combined pH/impedance
esting.33–35 The Rome III criteria for functional heart-
urn are (1) burning retrosternal discomfort or pain; (2)
bsence of evidence of that gastroesophageal acid reflux
s the cause of the symptom; (3) absence of histopathol-
gy-based esophageal motility disorders; and (4) that the
riteria are fulfilled for the last 3 months with symptom
nset 6 months before diagnosis.58 Although the basis
f these symptoms is unknown, it is believed that the
athophysiology involves visceral hypersensitivity and al-
ered central nervous system pain modulation, often in
he setting of psychologic comorbidity.58 – 60
Diagnostic Evaluation of Persistent
Symptoms
For patients with esophageal reflux symptoms
hat persist on PPI therapy, the goal is to determine
hether there is reflux disease, what the mechanism
ight be, and if there is not reflux disease, to perform
ther appropriate evaluation (Figure 2). After consider-
tion of serious non-GI pathology and ensuring correct
edication dosing, upper endoscopy is performed. It is
mportant to recognize the yield of this procedure for
tructural disease is low, with only 0.2% of patients hav-
ng esophageal cancer, 10% with persistent esophagitis,
nd 5%–10% with Barrett’s esophagus.3,17,61,62 It is also
easonable to perform at least five esophageal biopsies to
xclude eosinophilic esophagitis, even if the esophageal
ucosa seems to be normal.63,64 Eosinophilic esophagitis
as been reported in 1%– 8% of the PPI-refractory patient
opulation undergoing upper endoscopy.3,65– 69 If the up-
er endoscopy is normal, then the character and acidity
f esophageal refluxate is determined. pH/impedance
esting is most useful in this context.8,33–35 High-resolu-
ion esophageal manometry can also be considered at
his point because esophageal dysmotility may manifest
ith reflux symptoms, but the yield of this test in this
etting is unclear.8,57,70
Whether pH/impedance should be performed on or off
PI therapy is a matter of debate, and some subjects may
ltimately undergo the examination twice, once off ther-
py and once on, to gain a more complete understanding
f their reflux profile.8,33–35,70 –73 If there is ongoing esoph-
geal acid exposure on therapy, then the patient truly has
efractory acid reflux and may be a candidate for further
ntensification of medical therapy, or consideration of
perative therapy. In the appropriate clinical context, an
valuation for gastrinoma should be considered. If there
s excess nonacidic reflux that correlates with symptoms,
hen the patient has nonacid reflux, which may be the
tiology of the symptoms. If there is no evidence of
athologic acidic reflux, but symptoms correlate strongly






























Mini-Reviews and Perspectives continueditive esophagus. Finally, if there is neither pathologic
eflux nor symptom correlation, then the patient does
ot have reflux and other causes should be sought. In
his situation, functional heartburn or functional chest
ain is the most common diagnosis.33–35,58
Therapeutic Options
As noted, the escalation of PPI therapy beyond
ID dosing is of unproven utility, and the vast majority
f GERD subjects on BID dosing normalize esophageal
cid exposures. Although early work suggested that the
igure 2. An approach to diagnosis and treatment of the patient with PP
nsuring proper medication use, upper endoscopy with biopsy is p
onacid-related etiology is determined. If the upper endoscopy is norm
H/impedance testing. At this point, esophageal manometry can also b
atient has refractory acid reflux and treatment is either intensification
eflux, which correlates with symptoms, then the patient has nonacid re
eflux, but symptoms correlate strongly with physiologic reflux, then the
f reflux with no symptom correlation, then the patient does not hav
onesophageal etiology should be considered. For each of these last 2ddition of nighttime H2 receptor antagonists was ben- aficial,74 follow-up studies demonstrated early tolerance
imiting utility,75 and routine administration of night-
ime H2 blocker is not recommended.8 Several classes of
edications have been proposed as adjunct therapy for
ubjects with residual symptoms on PPI (Figure 1). Al-
hough some of these therapies have data supporting
heir use as monotherapy in the setting of GERD, data
upporting their use as adjunct therapy with PPI are
argely lacking. The therapy chosen corresponds with the
resumed mechanism(s) of the residual GERD symp-
oms, and options can be divided into those currently
actory GERD symptoms. After excluding serious non-GI pathology and
ed. If the upper endoscopy is abnormal, either an acid-related or
n the character and acidity of esophageal refluxate is determined with
nsidered. If pH/impedance testing reveals excess acid reflux, then the
dical therapy or consideration of surgery. If there is excess nonacidic
herapeutic considerations are the same. If there is a normal amount of
nt has a hypersensitive esophagus. Finally, if there is a normal amount
ux and likely has functional heartburn or functional chest pain, or a
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1
Currently Available
Among the currently available therapeutic op-
ions for the treatment of GERD symptoms are (1) con-
ersion to a different/more potent acid suppressive regi-
en, (2) bile salt binders, (3) promotility agents, (4)
aclofen, (5) mucosal protectants, and (6) centrally acting
ain modulators, such as tricyclic agents.
Although data support modest differences between the
PIs with respect to healing rates for mucosal disease
hen given in once daily doses,1,2 no data demonstrate a
enefit in switching from 1 brand to another in symp-
omatic nonerosive patients already receiving BID dos-
ng. Some data do suggest that in subjects refractory to
nce daily PPI, a switch to a different once daily PPI may be
s effective as BID therapy with the initial agent, and such
therapeutic trial may be warranted in the subject refrac-
ory to once daily PPI before institution of BID therapy.76
therwise, further manipulation of PPI dosing is not likely
o be fruitful. In healthy volunteers, discontinuation of PPI
herapy has been shown to cause increased reflux symptoms
termed rebound acid hypersecretion).77 Although the im-
act of medication discontinuation in the PPI-refractory
atient population is not well described, it seems prudent to
void starting and stopping PPI therapy in nonerosive pa-
ients who do not respond to this class of medications.77,78
Administration of bile salt binders assumes reflux of
ile salts in the acid suppressed patient exacerbates
sophageal pain. No data support the efficacy of adding
ile salt binders in this clinical setting.
Although promotility agents might address poor peri-
talsis as well as gastroparesis as potential etiologies of
orsened reflux, there is currently a paucity of available
ell-tolerated promotility agents. Given the side effect
rofile of metoclopramide79 and its unclear efficacy as an
ntireflux agent, its use as an adjunct to PPI therapy
annot be advocated. Similarly, the side effect profile and
achyphylaxis observed with erythromycin use make this
poor choice for chronic therapy. In short, although a
romotility agent is conceptually appealing, currently
vailable therapeutics are lacking.
Baclofen is a GABA B receptor agonist that inhibits
LESRs. This medication has the theoretical advantage of
nhibiting acidic, nonacidic, and mixed reflux. In placebo-
ontrolled studies, baclofen decreases esophageal acid
xposures in the short term as monotherapy, although its
alue as an adjunct to PPI therapy administered chroni-
ally is unclear.80 Its significant side effect profile (dizzi-
ess, nausea, vomiting, somnolence, and other central
ervous system symptoms) is generally reversible on ces-
ation of therapy.
Mucosal protectants, such as sucralfate, may be given
mpirically as adjuncts to PPI therapy. Such medications
re well tolerated, but their short dwell time in the s
2
sophagus and lack of proven efficacy in combination
ith PPI make their incremental benefit unclear.
Centrally acting agents such as tricyclic antidepres-
ants are attractive candidates, owing both to their pain-
odulating properties as well as the treatment of any
nderlying depressive symptoms. Although data substan-
iate the potential for these therapeutic agents in a re-
ated condition, noncardiac chest pain,81 few data are
vailable in PPI-refractory GERD or functional heartburn. A
mall uncontrolled series of subjects with persistent GERD
ymptoms but no objective evidence of ongoing reflux fol-
owing Nissen fundoplication demonstrated a 50% response
o tricyclics.82
Surgical antireflux procedures are unquestionably ef-
ective at diminishing episodes of reflux and improving
ymptomatology in subjects with documented reflux dis-
ase. However, subjects completely unresponsive to PPI
herapy have demonstrated poorer outcomes after anti-
eflux surgery,83 and caution is advised in the consider-
tion of this procedure in such a patient. A recent series
f subjects with normal esophageal acid exposures but
bnormal impedance suggests that impedance monitor-
ng may aid in the selection of PPI-refractory subjects
ho benefit from surgical antireflux procedures.84
Under Development
Several agents currently under development may
ugment our current limited therapeutic choices in PPI
efractory patients. The development of more potent acid
uppression may aid the small proportion of subjects with
ersistently elevated acid exposures despite PPI therapy.
otassium-competitive acid blockers work through compet-
tive inhibition of the H-K ATPase of parietal cells. While
harmacodynamic studies suggest that these agents should
ave rapid onset of vigorous acid suppression, randomized
ata to date do not show superiority over PPIs in subjects
ith nonerosive disease.85 New GABA B receptor agonists
re currently under development, which may allow the ben-
ficial effects of a baclofen-like compound, without the
ame degree of central side effects.86,87 Metabotropic gluta-
ate receptor-5 (MGluR5) modulators decrease the occur-
ence of tLESRs and increase LES pressure. Proof-of-princi-
le studies demonstrate that administration of a MGluR5
odulator was associated with a decrease in number and
uration of symptomatic reflux episodes in subjects with
ERD.88
Conclusion
Persistent reflux symptoms in the face of PPI
herapy are common in subjects treated for GERD, and
ost subjects will not demonstrate pathologically ele-
ated acid exposures. Multiple pathophysiologic mecha-
isms have been proposed to account for these persistent





























Mini-Reviews and Perspectives continuedersistent reflux symptoms while on PPIs revolves around
xcluding alternative diagnoses and isolating the likely
echanism(s) of symptoms. A variety of therapeutic mo-
alities are available to the physician and may be tailored
o the symptom complex and postulated mechanism of the
esidual symptoms. In general, scant literature is available
n which to base therapeutic decisions. Several new classes
f medications are under investigation, which may alter our
pproach to the management of these subjects.
Supplementary Material
Note: The first 5 references associated with this
rticle are available below in print. The remaining refer-
nces accompanying this article are available online only
ith the electronic version of the article. To access the
emaining references, visit the online version of Gastroen-
erology at www.gastrojournal.org, and at doi:10.1053/
.gastro.2010.05.016.
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